BTIG Maintains Buy on Macrogenics, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Kaveri Pohlman maintains a Buy rating on Macrogenics (NASDAQ:MGNX) but lowers the price target from $24 to $9.
May 24, 2024 | 5:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BTIG analyst Kaveri Pohlman maintains a Buy rating on Macrogenics but significantly lowers the price target from $24 to $9, indicating a more cautious outlook.
The significant reduction in the price target from $24 to $9 suggests a more cautious outlook on Macrogenics' future performance, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100